Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLADE-PCI trial of liposomal alendronate during PCI in patients with type 2 diabetes mellitus
MOH_2017-05-21_000440Phase 2Recruiting
- Sponsor
- BioRest
- Start
- Jul 2016
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronary restenosis comparing LABR-312 escalating dose with Placebo (2 arms). Primary endpoint: Percent neointimal hyperplasia volume. Started Jul 2016; status: recruiting.
02
Drugs
Liposomal alendronate
03
Conditions
coronary restenosis
Beyond the preview
Go deeper on MOH_2017-05-21_000440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-21_000440.